KALA BIO, Inc. KALA
Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026
KALA BIO, Inc. (KALA) is a healthcare company listed in the US with a market value of about $89479.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is future growth (0/5).
Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -159%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 494% above the current price.
About KALA BIO
KALA BIO is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2017. Revenue went from $45000 in 2015 to $4M in 2022, growth of about 89.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 436% over three years (dilution for shareholders).
Score: 1.0 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $4M | $11M | $6M | $6M | — | $0 | $0 |
| Net income | -$27M | -$39M | -$42M | -$45M | -$143M | -$104M | -$94M | -$67M | -$42M | -$33M |
| Free cash flow | — | — | — | — | — | — | -$94M | -$56M | -$35M | -$28M |
| EPS (diluted) | $-39.72 | $-121.80 | $-208.20 | $-353.76 | $-1299.84 | $-1182.72 | $-1640.35 | $-1479.88 | $-2204.97 | $-16682.88 |
| Net margin | — | — | — | -1151.6% | -1268.7% | -1639.8% | -1553.3% | — | — | — |
| ROIC | -442.2% | -72.6% | -71.5% | -103.6% | -104.9% | -43.1% | -65.7% | -28.3% | -28.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is KALA BIO stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 494% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does KALA BIO pay a dividend?
Not currently.
Is KALA BIO a good stock to buy?
We do not give buy or sell advice. KALA BIO scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.